Abstract
Polycystic kidney diseases (PKDs) represent a group of progressive genetic renal disorders that are characterized by the development of renal cysts that lead to end-stage renal disease. The rapid advance in our understanding of the pathogenesis of PKDs is revealing possible targets to slow down the progression of PKD. Among them, the epidermal growth factor receptor (EGFR) family members (ErbBs) as well as their ligands, such as EGF, HB-EGF, TGF-α, have emerged as important mediators of cystic formation and growth in PKD. ErbB receptors are either overexpressed or mislocated to the apical surface of cystic tubular epithelium in PKD instead of the basolateral localization seen in the normal adult kidney. Preclinical studies have demonstrated that inhibition of ErbB tyrosine kinase activity and/or reduced ErbB ligand availability significantly reduced cystogenesis in several murine PKD models (pcy, jck and cpk) and in the Han: SPRD rat ADPKD model. In this review, we will discuss the expression patterns, possible roles and related signaling molecules of the ErbB axis in PKD and the pharmaceutical potentials for future therapeutic development.
Keywords: PKD, ErbBs, expression, function, signaling pathways, therapies
Current Signal Transduction Therapy
Title: The ErbB Receptors and Their Ligands in PKD, an Overview
Volume: 5 Issue: 2
Author(s): Fenghua Zeng and Raymond C. Harris
Affiliation:
Keywords: PKD, ErbBs, expression, function, signaling pathways, therapies
Abstract: Polycystic kidney diseases (PKDs) represent a group of progressive genetic renal disorders that are characterized by the development of renal cysts that lead to end-stage renal disease. The rapid advance in our understanding of the pathogenesis of PKDs is revealing possible targets to slow down the progression of PKD. Among them, the epidermal growth factor receptor (EGFR) family members (ErbBs) as well as their ligands, such as EGF, HB-EGF, TGF-α, have emerged as important mediators of cystic formation and growth in PKD. ErbB receptors are either overexpressed or mislocated to the apical surface of cystic tubular epithelium in PKD instead of the basolateral localization seen in the normal adult kidney. Preclinical studies have demonstrated that inhibition of ErbB tyrosine kinase activity and/or reduced ErbB ligand availability significantly reduced cystogenesis in several murine PKD models (pcy, jck and cpk) and in the Han: SPRD rat ADPKD model. In this review, we will discuss the expression patterns, possible roles and related signaling molecules of the ErbB axis in PKD and the pharmaceutical potentials for future therapeutic development.
Export Options
About this article
Cite this article as:
Zeng Fenghua and C. Harris Raymond, The ErbB Receptors and Their Ligands in PKD, an Overview, Current Signal Transduction Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157436210791112145
DOI https://dx.doi.org/10.2174/157436210791112145 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multiple Mechanisms of Cytokine Action in Neurodegenerative and Psychiatric States: Neurochemical and Molecular Substrates
Current Pharmaceutical Design Treatment of Anaplastic Thyroid Cancer: Is there a Role for PPARγ Agonists?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Developing Practical Therapeutic Strategies that Target Protein SUMOylation
Current Drug Targets The Protective Effects of Extra Virgin Olive Oil on Immune-mediated Inflammatory Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Extrapituitary Actions of GnRH Antagonists: Prospects for in vitro Fertilization Programs
Current Pharmaceutical Design Circadian Cycle and Chronotherapeutics: Recent Trend for the Treatment of Various Biological Disorders
Recent Patents on Drug Delivery & Formulation Neurotrophic Factors in Combination: A Possible new Therapeutic Strategy to Influence Pathophysiology of Spinal Cord Injury and Repair Mechanisms
Current Pharmaceutical Design Lifelong Endocrine Fluctuations and Related Cognitive Disorders
Current Pharmaceutical Design The Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments
Current Neuropharmacology Molecular Pharmacology and Pharmacogenomics of Artemisinin and its Derivatives in Cancer Cells
Current Drug Targets Antioxidant Food Supplements and Obesity-Related Inflammation
Current Medicinal Chemistry Meet Our Editor:
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Environmental Chemicals and Breast Cancer Risk – A Structural Chemistry Perspective
Current Medicinal Chemistry Classification of Human Pregnane X Receptor (hPXR) Activators and Non-Activators by Machine Learning Techniques: A Multifaceted Approach
Combinatorial Chemistry & High Throughput Screening The Brain-Immune-Gut Triangle: Innate Immunity in Psychiatric and Neurological Disorders
Current Immunology Reviews (Discontinued) Recent Advances in the Development of Antimicrobial Peptides (AMPs): Attempts for Sustainable Medicine?
Current Medicinal Chemistry Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
Current Diabetes Reviews NF-κ B and Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Nutritional Aspects Relating to the Developmental Origins of Health and Disease
Current Women`s Health Reviews Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer
Current Cancer Drug Targets